Actively Recruiting
Phase 1 Study of Oral INCB123667 in Adults With Moderate or Severe Liver Impairment to Evaluate Safety and Drug Behavior
Led by Incyte Corporation · Updated on 2026-06-16
16
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety and how the body processes the drug INCB123667 when taken orally by adults with moderate or severe liver impairment. This Phase 1, open-label study includes participants with different levels of liver dysfunction to understand the drugs effects and safety in these groups. Participants are divided into two groups one with moderate hepatic impairment and another with severe hepatic impairment. Each participant receives a single oral dose of INCB123667. The study runs from May 2026 to April 2027, with each participant monitored for up to approximately 2.5 months to assess drug levels and safety. During the study, participants will undergo medical history reviews, physical exams, vital sign checks, ECGs, and lab tests to monitor their liver function and overall health. Researchers will measure drug concentrations in the blood and record any treatment-related side effects. Participants involvement includes signing consent forms and adhering to study protocols, with safety closely tracked throughout the study period.
CONDITIONS
Brief Title
A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment
Research Team
I
Incyte Corporation Call Center (US)
I
Incyte Corporation Call Center (ex-US)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
